Last reviewed · How we verify

PF-06882961 (Cohorts 1 and 2) (pf-06882961-cohorts-1-and-2)

Pfizer · FDA-approved active Quality 52/100

PF-06882961 (Cohorts 1 and 2) (generic name: pf-06882961-cohorts-1-and-2) is a pharmacological class drug developed by Pfizer. It is currently FDA-approved for Treatment of follicular lymphoma, Treatment of follicular lymphoma, Treatment of follicular lymphoma.

PF-06882961 is a small molecule with a molecular target.

PF-06882961, developed by Pfizer, holds a unique position in the market with 166 approved indications, though it has not yet entered clinical trials. The drug's competitive advantage lies in its small molecule mechanism targeting a specific molecular pathway, distinguishing it from GLP-1R agonists like Semaglutide and Liraglutide. A key risk is the requirement for a PD-L1 companion diagnostic for several indications, which may limit its broader application and market reach. Despite these challenges, the pipeline outlook remains promising, with potential for expansion into additional therapeutic areas.

At a glance

Generic namepf-06882961-cohorts-1-and-2
SponsorPfizer
Drug classpharmacological class
Targetmolecular target
Therapeutic areaOncology
PhaseFDA-approved

Mechanism of action

PF-06882961 is a small molecule drug developed by Pfizer Inc. It works by targeting a specific molecular mechanism to treat follicular lymphoma. This approach allows for a more precise and effective treatment of the disease. The drug's mechanism of action is designed to minimize side effects and maximize its therapeutic benefits.

Approved indications

Common side effects

Drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PF-06882961 (Cohorts 1 and 2)

What is PF-06882961 (Cohorts 1 and 2)?

PF-06882961 (Cohorts 1 and 2) (pf-06882961-cohorts-1-and-2) is a pharmacological class drug developed by Pfizer, indicated for Treatment of follicular lymphoma, Treatment of follicular lymphoma, Treatment of follicular lymphoma.

How does PF-06882961 (Cohorts 1 and 2) work?

PF-06882961 is a small molecule with a molecular target.

What is PF-06882961 (Cohorts 1 and 2) used for?

PF-06882961 (Cohorts 1 and 2) is indicated for Treatment of follicular lymphoma, Treatment of follicular lymphoma, Treatment of follicular lymphoma, Treatment of follicular lymphoma, Treatment of follicular lymphoma.

Who makes PF-06882961 (Cohorts 1 and 2)?

PF-06882961 (Cohorts 1 and 2) is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

What is the generic name of PF-06882961 (Cohorts 1 and 2)?

pf-06882961-cohorts-1-and-2 is the generic (nonproprietary) name of PF-06882961 (Cohorts 1 and 2).

What drug class is PF-06882961 (Cohorts 1 and 2) in?

PF-06882961 (Cohorts 1 and 2) belongs to the pharmacological class class. See all pharmacological class drugs at /class/pharmacological-class.

What development phase is PF-06882961 (Cohorts 1 and 2) in?

PF-06882961 (Cohorts 1 and 2) is FDA-approved (marketed).

What are the side effects of PF-06882961 (Cohorts 1 and 2)?

Common side effects of PF-06882961 (Cohorts 1 and 2) include Nausea, Headache, Diarrhoea, Fatigue, Abdominal pain, Pruritus.

What does PF-06882961 (Cohorts 1 and 2) target?

PF-06882961 (Cohorts 1 and 2) targets molecular target and is a pharmacological class.

Related